ScripThe UK's Izana Bioscience is the latest company to evaluate an immunomodulator as a treatment for coronavirus, and has initiated trials in Italy of its late-stage granulocyte-macrophage colony stimu
ScripThe IFPMA has appointed Greg Perry as its new assistant director general, effective mid-February. Perry will have responsibility for IFPMA’s external outreach and stakeholder engagement in global
ScripThe progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer
ScripCel-Sci Corp. and Ergomed PLC have voiced relief at the FDA's decision to remove the clinical hold placed on a Phase III study evaluating Multikine (Leukocyte Interleukin, Injection) in head a